Zeria To Test Old Cancer Vaccine For End-Stage Cervical Cancer
This article was originally published in PharmAsia News
Executive Summary
Zeria Pharmaceutical plans clinical trials in Japan, South Korea and Taiwan next year of a decades-old Japan cancer vaccine, using a higher concentration of it as a treatment for end-stage cervical cancer.
Zeria Pharmaceutical plans clinical trials in Japan, South Korea and Taiwan next year of a decades-old Japan cancer vaccine, using a higher concentration of it as a treatment for end-stage cervical cancer. The compound to be tested is the Maruyama vaccine developed in 1981, but which failed efficacy trials. Zeria launched a higher concentration of the Maruyama compound in 1991 as Ancer for preventing leukopenia in radiotherapy patients. The compound has cleared trials for different stages of cervical cancer, but now is to be tested on end-stage patients to make sure it prolongs life. (Click here for more - a subscription may be required
)
"Zeria To Start New Trial Of Cervical Cancer Drug" - Nikkei (Japan) (8/16/2013)